CLNN Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 geg. 2024 @ 23:00):

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics...

Stats
Šios dienos apimtis	954 834
Vidutinė apimtis	956 727
Rinkos kapitalizacija	56.12M
EPS	$0 ( 2024-03-11 )
Kita pelno data	( $-0.0900 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.930
ATR14	$0.00200 (0.46%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-24	General Resonance Llc	Sell	10 000	Common Stock
2024-04-09	General Resonance Llc	Sell	7 500	Common Stock
2024-04-09	General Resonance Llc	Sell	7 500	Common Stock
2024-04-09	General Resonance Llc	Sell	7 500	Common Stock
2024-03-11	Kiernan Matthew	Buy	29 481	Stock Options (Right to buy)

INSIDER POWER
99.19
Last 99 transactions
Buy: 46 168 962 \| Sell: 166 230

Tūris Koreliacija

Ilgas: -0.13 (neutral)

Trumpas: 0.98 (very strong)

Signal:(60.862) Expect same movement, but be aware

Clene Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
ATNF	0.907
CMTL	0.906
ADN	0.906
MAGS	0.905
PROG	0.904
BEEM	0.901
CTMX	0.901
OPINL	0.901
INVZ	0.898
REFR	0.897

10 Labiausiai neigiamai susiję koreliacijos
TIOA	-0.905
LFST	-0.896
TIOAU	-0.895
SWAV	-0.889
BRIVU	-0.888
LEDS	-0.885
VLAT	-0.885
JAQC	-0.885
CREX	-0.882
BRIV	-0.88

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Clene Inc. Koreliacija - Valiuta/Žaliavos

-0.73
( moderate negative )

-0.86
( strong negative )

0.00
( neutral )

0.30
( neutral )

Clene Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$654 000
Bruto pelnas:	$-1.17M (-179.20 %)
EPS:	$-0.470

FY	2023
Pajamos:	$654 000
Bruto pelnas:	$-1.17M (-179.20 %)
EPS:	$-0.470

FY	2022
Pajamos:	$473 000
Bruto pelnas:	$447 000 (94.50 %)
EPS:	$-0.230

FY	2021
Pajamos:	$723 000
Bruto pelnas:	$434 000 (60.03 %)
EPS:	$-0.160

Financial Reports:

No articles found.

Clene Inc.

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.